People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial ... among people taking the currently approved 2.4-mg dose, and 3.9% among people taking placebo, Novo said ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 ... starter dose and 42,960 yen for a 2.4 mg dose, Novo said. Patients in Japan will be ...

WASHINGTON — Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers ...

A breakthrough in weight loss medication is on the horizon. While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

Jan 17 (Reuters) - The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's (NOVOb.CO), opens ...

The company is spending billions to ramp up its Wegovy output as demand soars. "Emissions come with growth," said Katrine DiBona, corporate vice president of global public affairs and ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...